Sign In
Buy YMAB
$8.61
+0 (+0%)
At Close: Dec 15, 2025
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?
10:56am, Monday, 01'st Sep 2025
After reaching an important support level, Y-mAbs Therapeutics, Inc. (YMAB) could be a good stock pick from a technical perspective. YMAB recently experienced a "golden cross" event, which saw its 50-
NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigatin
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
08:45am, Friday, 08'th Aug 2025
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.21 per share a year ago.
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals. Clic
Y-mAbs (YMAB) Q2 Revenue Falls 14%
07:37am, Friday, 08'th Aug 2025
Y-mAbs Therapeutics (YMAB), a biopharmaceutical company focused on developing and commercializing antibody-based cancer therapies, reported its second quarter 2025 results on August 8, 2025. The compa
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
06:35am, Friday, 08'th Aug 2025
PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
06:44pm, Thursday, 07'th Aug 2025
NEW YORK , Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Y
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
07:30am, Thursday, 07'th Aug 2025
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
10:51am, Wednesday, 06'th Aug 2025
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley
04:49pm, Tuesday, 05'th Aug 2025
Morgan Stanley upgraded Y-mAbs Therapeutics to Equal Weight from Underweight with a price target of $8.60, up from $7, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per sha
Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord
04:49pm, Tuesday, 05'th Aug 2025
Canaccord downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $26, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
Y-mAbs Therapeutics downgraded to Perform from Outperform at Oppenheimer
04:47pm, Tuesday, 05'th Aug 2025
Oppenheimer analyst Jeff Jones downgraded Y-mAbs Therapeutics without a price target to Perform from Outperform after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in c
Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline
03:28pm, Tuesday, 05'th Aug 2025
Brookline analyst Kemp Dolliver downgraded Y-mAbs Therapeutics to Hold from Buy with an $8.60 price target after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
Y-mAbs Therapeutics downgraded to Hold from Buy at Truist
03:26pm, Tuesday, 05'th Aug 2025
Truist downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $14, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
